Compare ROIV & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | CFR |
|---|---|---|
| Founded | 2014 | 1868 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 8.1B |
| IPO Year | 2021 | N/A |
| Metric | ROIV | CFR |
|---|---|---|
| Price | $28.81 | $135.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 13 |
| Target Price | $27.56 | ★ $143.08 |
| AVG Volume (30 Days) | ★ 6.3M | 520.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $9.72 |
| Revenue Next Year | $385.85 | $4.70 |
| P/E Ratio | ★ N/A | $14.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $100.31 |
| 52 Week High | $30.03 | $148.97 |
| Indicator | ROIV | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 37.70 |
| Support Level | $20.46 | $134.54 |
| Resistance Level | N/A | $146.95 |
| Average True Range (ATR) | 0.95 | 3.51 |
| MACD | -0.00 | -1.19 |
| Stochastic Oscillator | 66.80 | 22.49 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.